TRAF7
protein-codingTNF receptor associated factor 7, the group of TNF receptor associated factors|Ring finger proteins|Zinc fingers TRAF-type|WD repeat domain containing
Gene summary
Tumor necrosis factor (TNF; see MIM 191160) receptor-associated factors, such as TRAF7, are signal transducers for members of the TNF receptor superfamily (see MIM 191190). TRAFs are composed of an N-terminal cysteine/histidine-rich region containing zinc RING and/or zinc finger motifs; a coiled-coil (leucine zipper) motif; and a homologous region that defines the TRAF family, the TRAF domain, which is involved in self-association and receptor binding.[supplied by OMIM, Apr 2004]
- RFWD1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~22.4 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0032572
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0032572
Submitter: Ambry Genetics
Inheritance Pattern: AD
Disease ID:MONDO:0032572
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0032572
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0032572
Submitter: Illumina
Inheritance Pattern: AD
Disease ID:MONDO:0800439
Submitter: ClinGen
TRAF7 is a known mediator of the MAPK and NFKB signaling pathways and is involved in multiple biologic processes, such as ubiquitination. *TRAF7* was first reported in relation to autosomal dominant syndromic complex neurodevelopmental disorder in 2018 (Tokita et al., PMID: 29961569). This is a multisystemic developmental disorder with developmental delay/intellectual disability, variable cardiac and digital anomalies, and recognizable facial features. Some patients may have autism spectrum disorder, seizures, hearing loss or ocular abnormalities. Thirteen *de novo* missense variants that have been reported in 16 probands in 2 publications (PMIDs: 29961569, 32376980) are included in this curation. More genetic evidence is available in the literature (PMIDs: 34513876, 37067385, 38569228, 38612512) but the maximum score for genetic evidence (12 points) has been reached. Several variants are recurrent (including p.Arg655Gln and p.Phe617Leu), and most cluster within the WD40 repeats of the TRAF7 protein, suggesting dominant-negative and/or gain-of-function effects. This gene-disease relationship is also supported by zebrafish and xenopus *traf7* model systems (PMID: 37043537), and functional studies demonstrating transcriptional changes and altered ERK signaling in the presence of pathogenic *TRAF7* variants (PMID: 29961569, 32376980). In summary, there is definitive evidence supporting the relationship between *TRAF7* and autosomal dominant syndromic complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panels on the meeting date September 6, 2023 (SOP Version 9).
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Craniofacial; Musculoskeletal; Neurologic; Ophthalmologic
Intervention: Cardiovascular
Rationale: Among other findings, individuals have been described with heart anomalies (eg, including structural anomalies and arrthymia), and awareness may allow prompt diagnosis and management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to TRAF7 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_032271.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 44 | 3 | 50 | ||
| missense | 7 | 20 | 144 | 19 | 1 | 191 |
| nonsense | 4 | 4 | ||||
| start loss | 1 | 1 | ||||
| frameshift | 5 | 5 | ||||
| splice donor/acceptor (+/-2bp) | 13 | 13 | ||||
| Total | 7 | 20 | 170 | 63 | 4 | 264 |
Highest pathogenic variant AF is 6.8561997e-7
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_115647.2 | 20 | MANE Select | |
| Ensembl | ENSP00000318944.6 | 20 | MANE Select | |
| Ensembl | ENSP00000457735.1 | 3 | Standard | |
| Ensembl | ENSP00000479297.1 | 3 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Immune System
- Adaptive Immune System
- Antigen processing: Ubiquitination & Proteasome degradation
- Class I MHC mediated antigen processing & presentation
- TNFalpha
Biological Process
- ribosomal large subunit assembly
- activation of MAPKKK activity
- apoptotic process
- Notch signaling pathway
- protein ubiquitination
Molecular Function
- ubiquitin-protein transferase activity
- protein binding
- zinc ion binding
Cellular Component
- ubiquitin ligase complex
- nucleolus
- plasma membrane
- cytoplasmic vesicle
- intracellular membrane-bounded organelle
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000326181
- Coding exons
- 20
- Length
- 22432
- Individuals with no LoFs
- 125719
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 23
- Defined
- 125742
- p
- 0.0000915
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 3.26 | 248 | 441 | 0.563 | 0.0000289 | 4385 |
| Missense (PolyPhen) | 40 | 130.65 | 0.30616 | 1396 | ||
| Synonymous | -1.53 | 215 | 188 | 1.14 | 0.0000140 | 1281 |
| Loss of Function | 4.24 | 11 | 39.9 | 0.276 | 0.00000197 | 432 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.000063 | 0.000062 | rare |
| Latino/Admixed American | 0.000058 | 0.000058 | rare |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.000048 | 0.000046 | rare |
| European (Non-Finnish) | 0.000099 | 0.000097 | rare |
| South Asian | 0.000098 | 0.000098 | rare |
| Other | 0.00017 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: E3 ubiquitin ligase capable of auto-ubiquitination, following phosphorylation by MAP3K3. Potentiates MEKK3-mediated activation of the NF-kappa-B, JUN/AP1 and DDIT3 transcriptional regulators. Induces apoptosis when overexpressed. {ECO:0000269|PubMed:14743216, ECO:0000269|PubMed:15001576}.;
Recessive Scores
- pRec
- 0.141
Intolerance Scores
- LoFtool
- 0.468
- RVIS EVS
- -1.51
- RVIS percentile EVS
- 3.5
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- S
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.961
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |